Skip Navigation


European Heart Journal Advance Access originally published online on May 5, 2007
European Heart Journal 2007 28(11):1273-1274; doi:10.1093/eurheartj/ehm132
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/11/1273    most recent
ehm132v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bassand, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bassand, J.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm

Jean-Pierre Bassand

Department of Cardiology, University Hospital Jean Minjoz, Boulevard Fleming, 25000 Besançon, France

Corresponding author. Tel: +33 381 668 539; fax: +33 381 668 582. E-mail address: jpbassan@univ-fcomte.fr

This editorial refers to ‘Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction’{dagger} by D. Aronson et al., on page 1289

The first 10% of the full text of this article appears below.

Over the last two decades, major improvements in clinical outcome have been achieved in the management of acute coronary syndromes (ACS), with or without ST-segment elevation. In both these clinical settings, the pharmacological approach comprising anti-platelet agents, (or a combination thereof), anticoagulants, thrombolytic treatment in case of ST-elevation MI (STEMI) combined with mechanical or surgical revascularization or reperfusion, has led to a dramatic reduction in the rate of ischaemic events, namely death, death/myocardial infarction (MI), or death/MI/stroke. However, this has been achieved at the cost of a higher risk of bleeding complications, which were considered, until recently, to be inherent to ACS management, and to be a side effect devoid of serious clinical implications, except for intra-cranial bleeding. Bleeding complications were thought to be the price to pay for the improvement in the risk of ischaemic events, and were considered to be . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction
Doron Aronson, Mahmoud Suleiman, Yoram Agmon, Abeer Suleiman, Miry Blich, Michael Kapeliovich, Rafael Beyar, Walter Markiewicz, and Haim Hammerman
EHJ 2007 28: 1289-1296. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
J.-P. Bassand
The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes
Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C22 - C29.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Liron
Nosocomial anaemia
Eur. Heart J., October 2, 2007; 28(20): 2551 - 2551.
[Full Text] [PDF]